jeremiah@devisedesigns.com, Author at Corcept Therapeutics - Page 5 of 16

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 156 entries already.

Entries by jeremiah@devisedesigns.com

Hypercortisolism (Cushing syndrome)

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Frias et al. • 2023 • 7th annual Heart in Diabetes CME Conference

June 9, 2023

The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol

Greenstein & Hunt • 2023 • International Immunopharmacology

June 6, 2023

Hypercortisolism (Cushing syndrome)

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

Simeoli et al. • 2023 • European Congress of Endocrinology

June 5, 2023

Hypercortisolism (Cushing syndrome)

An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome

Badiu et al. • 2023 • European Congress of Endocrinology

June 4, 2023

Hypercortisolism (Cushing syndrome)

Absence of QT Prolongation Associated with Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Cushing Syndrome

Donegan et al. • 2023 • AACE 2023

June 3, 2023

Hypercortisolism (Cushing syndrome)

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Frias et al. • 2023 • AACE 2023

June 1, 2023

Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors

Mann et al. • 2023 • AACR 2023

April 17, 2023

Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators

Mallick et al • 2023 • Transl Res.

March 28, 2023

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

Alexander Olawaiye et al. • 2023 • SGO Annual Meeting 2023

March 26, 2023

Phase 1 Efficacy and Pharmacodynamic Results of Exicorilant + Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Michael Morris et al. • 2023 • ASCO GU Cancers Symposium 2023

February 16, 2023

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Your Privacy Choices